Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2011, Article ID 495025, 6 pages
http://dx.doi.org/10.4061/2011/495025
Clinical Study

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates

1Centre for Age-Related Medicine, Stavanger University Hospital, 4068 Stavanger, Norway
2Wolfson Centre for Age-Related Diseases, King's College London, London SE1 1UL, UK
3Research Unit, Department of Clinical Sciences, Malmö, University of Lund, Lund, Norway
4Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Molndal, Gothenburg, Sweden
5NVS Department, KI Alzheimer Disease Research Center, Karolinska Institutet, Novum, 14186 Stockholm, Sweden
6Institute of Clinical Medicine, Akershus University Hospital, University of Oslo, Oslo, Norway

Received 7 April 2011; Revised 13 June 2011; Accepted 19 July 2011

Academic Editor: Lucilla Parnetti

Copyright © 2011 Ezra Mulugeta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg, “Cerebrospinal fluid and plasma biomarkers in Alzheimer disease,” Nature Reviews Neurology, vol. 6, no. 3, pp. 131–144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. H. W. Querfurth and F. M. LaFerla, “Alzheimer's disease,” New England Journal of Medicine, vol. 362, pp. 329–344, 2011. View at Google Scholar
  3. M. P. Mattson, “Pathways towards and away from Alzheimer's disease,” Nature, vol. 430, no. 7000, pp. 631–639, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Hiltunen, T. van Groen, and J. Jolkkonen, “Functional roles of amyloid-β protein precursor and amyloid-β peptides: evidence from experimental studies,” Journal of Alzheimer's Disease, vol. 18, no. 2, pp. 401–412, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. P. Mattson, “Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives,” Physiological Reviews, vol. 77, no. 4, pp. 1081–1132, 1997. View at Google Scholar · View at Scopus
  6. Y. W. Zhang, R. Thompson, H. Zhang, and H. Xu, “APP processing in Alzheimer's disease,” Molecular Brain, vol. 4, Article ID 21214928, p. 3, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Li, B. Wang, Z. Wang et al., “Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 40, pp. 17362–17367, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Lewczuk, H. Kamrowski-Kruck, O. Peters et al., “Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study,” Molecular Psychiatry, vol. 15, no. 2, pp. 138–145, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Gabelle, S. Roche, C. Gény et al., “Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid,” Brain Research, vol. 1357, no. C, pp. 175–183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Zetterberg, U. Andreasson, O. Hansson et al., “Elevated cerebrospinal fluid BACE1 activity in incipient alzheimer disease,” Archives of Neurology, vol. 65, no. 8, pp. 1102–1107, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Olsson, K. Höglund, M. Sjögren et al., “Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients,” Experimental Neurology, vol. 183, no. 1, pp. 74–80, 2003. View at Publisher · View at Google Scholar
  12. M. E. Kalaitzakis, A. J. Walls, R. K. B. Pearce, and S. M. Gentleman, “Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other Parkinsonian syndromes,” Neurobiology of Disease, vol. 41, no. 2, pp. 377–384, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Mulugeta, E. Londos, C. Ballard et al., “CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 82, no. 2, pp. 160–164, 2011. View at Publisher · View at Google Scholar
  14. D. Aarsland, A. Rongve, S. Piepenstock Nore et al., “Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria,” Dementia and Geriatric Cognitive Disorders, vol. 26, no. 5, pp. 445–452, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. C. F. Lippa, J. E. Duda, M. Grossman et al., “DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers,” Neurology, vol. 68, no. 11, pp. 812–819, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Aarsland, C. Ballard, Z. Walker et al., “Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial,” The Lancet Neurology, vol. 8, no. 7, pp. 613–618, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Aarsland, E. Londos, and C. Ballard, “Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity,” International Psychogeriatrics, vol. 21, no. 2, pp. 216–219, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. I. G. McKeith, D. W. Dickson, J. Lowe et al., “Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium,” Neurology, vol. 65, no. 12, pp. 1863–1872, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. G. McKhann, D. Drachman, and M. Folstein, “Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease,” Neurology, vol. 34, no. 7, pp. 939–944, 1984. View at Google Scholar
  20. M. Emre, “Dementia associated with Parkinson's disease,” Lancet Neurology, vol. 2, no. 4, pp. 229–237, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. A. F. Jorm, “The informant questionnaire on cognitive decline in the elderly (IQCODE): a review,” International Psychogeriatrics, vol. 16, no. 3, pp. 275–293, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. R. J. Bateman, G. Wen, J. C. Morris, and D. M. Holtzman, “Fluctuations of CSF amyloid-β levels: implications for a diagnostic and therapeutic biomarker,” Neurology, vol. 68, no. 9, pp. 666–669, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. R. M. Nitsch, B. E. Slack, R. J. Wurtman, and J. H. Growdon, “Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors,” Science, vol. 258, no. 5080, pp. 304–307, 1992. View at Google Scholar · View at Scopus
  24. R. M. Nitsch, S. A. Farber, J. H. Growdon, and R. J. Wurtman, “Release of amyloid β-protein precursor derivatives by electrical depolarization of rat hippocampal slices,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 11, pp. 5191–5193, 1993. View at Google Scholar · View at Scopus
  25. R. M. Nitsch, A. Deng, R. J. Wurtman, and J. H. Growdon, “Metabotropic glutamate receptor subtype mGlur1α stimulates the secretion of the amyloid β-protein precursor ectodomain,” Journal of Neurochemistry, vol. 69, no. 2, pp. 704–712, 1997. View at Google Scholar · View at Scopus
  26. S. A. Farber, R. M. Nitsch, J. G. Schulz, and R. J. Wurtman, “Regulated secretion of β-amyloid precursor protein in rat brain,” Journal of Neuroscience, vol. 15, no. 11, pp. 7442–7451, 1995. View at Google Scholar · View at Scopus
  27. P. R. Turner, K. O'Connor, W. P. Tate, and W. C. Abraham, “Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory,” Progress in Neurobiology, vol. 70, no. 1, pp. 1–32, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Sydow, A. Van Der Jeugd, F. Zheng et al., “Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic tau mutant,” Journal of Neuroscience, vol. 31, no. 7, pp. 2511–2525, 2011. View at Publisher · View at Google Scholar